Suvi Turunen1, Marja Vääräsmäki1, Maarit Leinonen2, Mika Gissler2,3, Tuija Männistö4, Eila Suvanto1. 1. Department of Obstetrics and Gynecology, PEDEGO Research Unit, Medical Research Center Oulu, University of Oulu and University Hospital of Oulu, Oulu, Finland. 2. Information Services Department, Finnish Institute of Health and Welfare, Helsinki, Finland. 3. Department of Neurobiology, Care Sciences and Society, Karolinska Institute, Stockholm, Sweden. 4. Northern Finland Laboratory Centre Nordlab, Oulu, Department of Neurobiology, Care Sciences and Society, Finland Karolinska Institute, Stockholm, Sweden.
Abstract
OBJECTIVE: Thyroid dysfunction affects up to 5-7% of all pregnancies. The rates of thyroid hormone use in nonpregnant population have substantially increased in recent years. The aim of this study was to assess possible changes in the use of levothyroxine substitution and antithyroid drugs over time in pregnant women. METHODS: The study data consisted of all singleton pregnancies (N = 736,873) between 2004 and 2016 in Finland collected from the Finnish Medical Birth Register. The Prescription Register and Special Refund Entitlement Register provided information on levothyroxine and antithyroid drug purchases. The annual rates of levothyroxine and antithyroid drug prescription redemptions were explored to estimate changes in exposure rates to thyroid medication from 2004 to 2016. Joinpoint regression analyses were performed to explore interannual variability in levothyroxine and antithyroid drug treatment. RESULTS: There was more than a five-fold increase in levothyroxine use during the study period; in 2004, 1.1% of pregnant women had levothyroxine treatment, and by 2016, the prevalence increased to 6.2%. In addition, we observed a slight increase in antithyroid medication during pregnancy, but antithyroid drug use during pregnancy overall was very rare. In 2004, 0.05% of pregnant women used antithyroid drugs, and by 2016, this percentage had increased to 0.14%. CONCLUSIONS: Our study shows that the rate of levothyroxine use in pregnancy has markedly increased. This suggests that tracing and screening relevant patients and awareness of thyroid disorders on pregnancy and their significance for the pregnancy outcome have increased and the threshold to treat thyroid disorders has declined.
OBJECTIVE: Thyroid dysfunction affects up to 5-7% of all pregnancies. The rates of thyroid hormone use in nonpregnant population have substantially increased in recent years. The aim of this study was to assess possible changes in the use of levothyroxine substitution and antithyroid drugs over time in pregnant women. METHODS: The study data consisted of all singleton pregnancies (N = 736,873) between 2004 and 2016 in Finland collected from the Finnish Medical Birth Register. The Prescription Register and Special Refund Entitlement Register provided information on levothyroxine and antithyroid drug purchases. The annual rates of levothyroxine and antithyroid drug prescription redemptions were explored to estimate changes in exposure rates to thyroid medication from 2004 to 2016. Joinpoint regression analyses were performed to explore interannual variability in levothyroxine and antithyroid drug treatment. RESULTS: There was more than a five-fold increase in levothyroxine use during the study period; in 2004, 1.1% of pregnant women had levothyroxine treatment, and by 2016, the prevalence increased to 6.2%. In addition, we observed a slight increase in antithyroid medication during pregnancy, but antithyroid drug use during pregnancy overall was very rare. In 2004, 0.05% of pregnant women used antithyroid drugs, and by 2016, this percentage had increased to 0.14%. CONCLUSIONS: Our study shows that the rate of levothyroxine use in pregnancy has markedly increased. This suggests that tracing and screening relevant patients and awareness of thyroid disorders on pregnancy and their significance for the pregnancy outcome have increased and the threshold to treat thyroid disorders has declined.
Authors: Tim I M Korevaar; Ryan Muetzel; Marco Medici; Layal Chaker; Vincent W V Jaddoe; Yolanda B de Rijke; Eric A P Steegers; Theo J Visser; Tonya White; Henning Tiemeier; Robin P Peeters Journal: Lancet Diabetes Endocrinol Date: 2015-10-20 Impact factor: 32.069
Authors: Martin I Surks; Eduardo Ortiz; Gilbert H Daniels; Clark T Sawin; Nananda F Col; Rhoda H Cobin; Jayne A Franklyn; Jerome M Hershman; Kenneth D Burman; Margo A Denke; Colum Gorman; Richard S Cooper; Neil J Weissman Journal: JAMA Date: 2004-01-14 Impact factor: 56.272
Authors: Spyridoula Maraka; Raphael Mwangi; Rozalina G McCoy; Xiaoxi Yao; Lindsey R Sangaralingham; Naykky M Singh Ospina; Derek T O'Keeffe; Ana E Espinosa De Ycaza; Rene Rodriguez-Gutierrez; Charles C Coddington; Marius N Stan; Juan P Brito; Victor M Montori Journal: BMJ Date: 2017-01-25
Authors: Helena Filipsson Nyström; Anne Lise Brantsæter; Iris Erlund; Ingibjörg Gunnarsdottir; Lena Hulthén; Peter Laurberg; Irene Mattisson; Lone Banke Rasmussen; Suvi Virtanen; Helle Margrete Meltzer Journal: Food Nutr Res Date: 2016-06-08 Impact factor: 3.894
Authors: Kjersti S Bakken; Kristina Randjelovic Nermo; Bjørn Gunnar Nedrebø; Tim I M Korevaar; Tor A Strand Journal: Endocr Connect Date: 2022-04-29 Impact factor: 3.221